Letter to the Editor: Is Emricasan (IDN‐6556), an Oral Pan‐Caspase Inhibitor, Ready for Controlled Trials?

Potential conflict of interest: Nothing to report. To the Editor: We read with interest the study by Garcia‐Tsao et al.1 regarding the impact of emricasan, a pan‐caspase inhibitor, on portal hypertension. We commend the authors for this investigation as there is an unmet need for medical therapies to reduce portal hypertension and its consequences. However, there are significant concerns that need clarification to adequately assess the impact of...